FDA Approves First 3D-Printed Drug Product
PTSM: Pharmaceutical Technology Sourcing and Management
Aprecia Pharmaceutical’s SPRITAM levetiracetam gains FDA approval for the treatment of epilepsy.
Aprecia Pharmaceuticals announced on Aug. 3, 2015 that FDA has approved SPRITAM levetiracetam, the first 3D-printed drug product, for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children with epilepsy.
SPRITAM is manufactured with Aprecia's ZipDose Technology platform, which uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid, the company reports. The approval marks the first time a drug product manufactured with this technology has been approved by the FDA, according to an Aprecia Pharmaceuticals news release.
ZipDose Technology enables the delivery of up to 1000 mg in a single dose, the company reports. Administration of even the largest strengths of levetiracetam with a sip of liquid. The product is expected to be available in the first quarter of 2016.
ZipDose Technology combines formulation science with the manufacturing capabilities of 3DP. Aprecia developed its ZipDose Technology platform using the 3DP technology that originated at Massachusetts Institute of Technology (MIT).
Source: Aprecia Pharmaceuticals
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
